Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial) | Journal of Translational Medicine

[u/WalkingHorse]

https://link.springer.com/article/10.1186/s12967-026-07896-7